New startup ideas · Health and bio · Healthcare and bio
startup idea
Pulsefold
A $40 home panel clinics accept in place of a routine lab draw.
Pulsefold is a consumer countertop device with disposable cartridges that returns a cardiometabolic panel (lipids, HbA1c, kidney markers) in minutes at home, sold through pharmacy chains, employers and Medicare Advantage plans rather than direct.
- Hardware
- Consumer
- $100B+ market
- Collapses a cost 10x
- US first
3/5
venture judge
3
similar startups, last 2 years (17 all-time)
96%
of 3 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$2,000 · 5 weeks · 27 prospects
For $2,000 and 5 weeks, prove that primary care practices will sign written acceptance of a home-collected panel and that self-insured employers will sign dated pilot LOIs, before a dollar goes into cartridge tooling.
Riskiest assumption · Primary care practices will commit in writing to accept an unsupervised home-collected cardiometabolic panel in place of the pre-visit lab draw, rather than politely praising the device and re-ordering the venous draw anyway
1Focus group: who and where
Two people per deal: the benefits director of a self-insured employer with 5,000+ employees and a diabetes management program whose members still make quarterly draw-station visits, and the medical director of that employer's contracted primary care group who decides what counts as a pre-visit panel
where to find 27 · Form 5500 filings, a public directory of self-insured health plans, filtered to large employers in two states; Business Group on Health membership, the association where exactly these benefits leaders sit; warm introductions through benefits consultants at Mercer and WTW, the channel these employers already buy through; state AAFP chapters to reach family-medicine medical directors for the acceptance test
2Sell first, build later
A first-cohort pilot slot, sold before the device exists: 200 diabetes program members get mailed cartridges in place of quarterly draw-station visits starting Q3 2027, results delivered in a format the employer's contracted clinic group has signed to accept, contingent on FDA clearance and CLIA waiver
the ask · $40 per mailed panel, billed to the employer per completed test, hardware subsidized by the channel
a real yes · A signed employer LOI with a dated 2027 start plus a signed clinician acceptance letter from their clinic group counts; 'send us more data', interest from a wellness committee, and unpaid clinician enthusiasm do not
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Clinician acceptance letter test
$1,400 · 14 days
Build the two-page clinician-facing result report (values, QC flags, collection chain, reference ranges) and a one-page acceptance letter stating the practice will take this format in place of the pre-visit draw for stable diabetes patients, contingent on FDA clearance and CLIA waiver. Run 12 paid 30-minute reviews at $100 honorarium with primary care physicians and medical directors recruited through state AAFP chapters and personal networks, and ask each to sign the letter on the call.
keep going if · 4 of 12 clinicians sign the acceptance letter; signatures, not favorable opinions
2. Sub-$15 cartridge quote check
$100 · 12 days
Send a one-page spec for a three-assay disposable microfluidic cartridge to four US contract manufacturers of microfluidic consumables and request written budgetary quotes at 100,000 units per year. This is a desk exercise the technical founder runs in parallel; it attacks the card's stated unit-cost risk before any tooling money moves.
keep going if · At least 1 written quote at or under $15 per cartridge at volume; none under $25 is a hard stop
3. Employer pilot LOI pitch
$500 · 21 days
Book 15 calls with benefits directors from the Form 5500 list, Business Group on Health contacts and Mercer or WTW introductions. Pitch a Q3 2027 pilot: mailed cartridges replacing quarterly draw-station visits for 200 diabetes program members at $40 per panel, with their contracted clinic group named in the LOI. The ask on every call is a signed LOI with a dated start, not feedback.
keep going if · 3 of 15 request the LOI draft and 2 sign within the window
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$0
no cash yet: take a signed commitment
how · No money can credibly move for an uncleared diagnostic, so collect paper instead: a non-binding LOI signed by the benefits director naming a Q3 2027 start date, 200 enrolled members, the $40 per-panel price and the contracted clinic group, paired with that clinic group's signed acceptance letter
what it reserves · One of three first-cohort pilot slots, the $40 per-panel price locked for the pilot term, and the named clinic group's result-format acceptance
refund · The LOI is non-binding, withdrawable in writing at any time, and expires automatically if the device is not FDA cleared and CLIA waived 60 days before the start date
target · 2 signed employer LOIs from 15 benefits-director conversations and 4 signed clinician acceptance letters from 12 reviews, within 5 weeks
before taking money · This is an FDA-regulated in vitro diagnostic: do not sell the device, take payment for it, or return any result to a patient or clinician before FDA clearance and a CLIA waiver, and keep every commitment in this test on contingent paper.
Go: build it if
2 signed employer LOIs with dated starts, 4 of 12 clinicians signed on acceptance, and at least 1 manufacturer quote at or under $15 per cartridge: raise the hardware round with the paper in hand
Kill: stop if
0 LOIs after 15 employer pitches, or fewer than 2 of 12 clinicians will sign under any conditions, or no cartridge quote under $25 at 100,000 units: stop
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
Your diabetes management members still drive to a draw station four times a year, and each draw-plus-visit runs your plan $200-400. I'm building Pulsefold, a countertop device that runs lipids, HbA1c and kidney markers at home, with results in a format your contracted clinic group signs to accept as the pre-visit panel. Before building, I'm signing three employers to a Q3 2027 pilot LOI, contingent on FDA clearance. Do you have 20 minutes this week to review the result format and pilot scope?
landing page
Replace the quarterly draw-station visit with a $40 home panel Pilot LOI: mailed cartridges for 200 diabetes program members at $40 per panel, results your contracted clinic group has signed to accept Book a 20-minute pilot scoping call
deposit terms
No payment is taken today: you sign a non-binding letter of intent naming a Q3 2027 pilot start, 200 enrolled diabetes program members, your contracted clinic group, and the $40 per-panel price. The LOI reserves one of three first-cohort pilot slots and locks that price for the pilot term. It expires automatically if Pulsefold is not FDA cleared and CLIA waived 60 days before the start date, and you may withdraw in writing at any time.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
74
Idea Score, 0-100 · raw 46.2 x 1.61
Active
competition: more crowded than 56% of ideas · headwind x0.72
+4.1
government priorities, secondary (50 matching grants)
Trend
54
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)23
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
72
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis100
- Moat axis100
- Neighbours still alive81
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were home, panel, clinics, accept, place, routine, lab, draw.
The idea in full
- What
- Pulsefold is a consumer countertop device with disposable cartridges that returns a cardiometabolic panel (lipids, HbA1c, kidney markers) in minutes at home, sold through pharmacy chains, employers and Medicare Advantage plans rather than direct. The value is not the reading but acceptance: a clinician-facing result format that primary care practices agree to take as the pre-visit panel. Consumers buy cartridges on subscription; channel partners subsidize the hardware.
- Why now
- Carevision Inc. (500global 500G MENA 11) is building 60-second cardiometabolic screening as a staffed platform and Adialante (yc X26) is pushing screening past access barriers, which shows payers now buy screening throughput; 130 companies entered this cluster in the last two years and none of the recent cohort ships consumer-owned panel hardware.
- Wedge: first customer and entry point
- One large employer's diabetes management population: replace their quarterly draw-station visit with mailed cartridges, and get that employer's contracted clinic group to accept the result.
- Path to 100x
- US routine outpatient lab and primary care testing is a $100B+ market and a home cartridge takes a $200-400 draw-plus-visit down to tens of dollars. Acceptance is two-sided: every practice that accepts a Pulsefold panel makes the device more worth owning, and every owner pressures the next practice to accept it, which is how one result format wins the rail rather than five.
- Ceiling
- Clinicians refuse to act on unsupervised home samples, and the device settles into the wellness gadget shelf where consumers churn after two cartridges.
- Closest real companies, as the generator saw them
- Carevision Inc. runs a screening station model that needs an operator and a site; Pulsefold puts the cartridge in the home and monetizes recurring consumables. Lumius (yc X26) does accessible 3D ultrasound, a different modality with no consumables loop.
- Main risk
- Cartridge unit economics stay above $15 and the 10x cost story against a standard lab panel never materializes.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
Two-sided clinician acceptance could win the result rail, but capital-heavy cartridges above $15 kill the 10x story outright.
Bootstrapper
1/5
Cartridge manufacturing at sub-$15 unit cost plus payer and pharmacy channel deals needs far more than two-person capital.
Operator
2/5
Value depends entirely on primary care practices agreeing to accept an unsupervised home sample as the pre-visit panel.
Technologist
3/5
Consumer cartridge chemistry for HbA1c and lipids is genuine hardware work, but the stated blocker is unit cost above $15, not defensibility.
Risk
2/5
The value claim depends on clinicians accepting unsupervised home samples plus channel partners like Medicare Advantage plans, two gatekeepers it does not control.
trends
2/5
Home cardiometabolic panels were equally buildable in 2023 and the cited proof points are two screening startups, not a dated regulatory or platform shift.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (home, panel, clinics, accept, place, routine, lab, draw): 17 all-time, 3 from the last two years. Same matching as Idea Check.
A primary care clinic where AI earns clinical autonomy
Empowering next-gen precision oncology with scalable, in-house AI biomarkers from routine pathology slides.
Membership-based health platform for clinical testing, diagnostics and MRI scans
Candle helps friends and couples grow closer daily in just 5 minutes.
Klinrisk finds progressive kidney disease early before kidney function is lost
Memory Lane Games: Mayo Clinic-award winning dementia platform turning memories into engaging personalised quiz games for monitoring and management of cognitive decline.
At-cost preventive health: Labs, Scans, Genetics, Supplements and Rx
Redcliffe Labs is India's Largest Omni-channel Diagnostics platform
Global at-home male fertility testing that delivers home comfort with lab accuracy — trusted by the world’s leading IVF clinics.
API for at-home clinical sample collection.
Operator of a software and logistics remote diagnostics company intended to offer at-home self-collected diagnostic testing services. The company integrates with clients so that they can offer at-home testing kits on behalf of patients to collect samples at home and send them back to partner labs, that are reviewed by licensed clinicians, thereby enabling customers to access remote diagnostics with secure infrastructure or preferred tech stack.
Online pets supplies for Latin America with over 4000 products & 20…
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1596
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
119
opportunities open now in the sector
- AmblyoGo" a 'Smart' Easy-to-use Occlusion Dose Monitor (ODM) for Amblyopia in Childrenawardhigh relevance
NIH / NEI · SBIR phase II · $1M · posted 2026-08-10
- A novel remote blood separation device for at-home plasma collection for HIV-1 testingawardhigh relevance
NIH / NCHHSTP · SBIR phase II · $995K · posted 2025-09-30
- Rapid and Highly Multiplexed Pathogen Detection for Sepsis Patients with Compressed Sensing and Digital PCRawardhigh relevance
NIH / NCHHSTP · SBIR phase I · $296K · posted 2026-09-30
NIH / NHLBI · SBIR phase II · $1M · posted 2026-08-10
- Developing a Learning Platform to Support Minimally Verbal Individuals with Autismawardhigh relevance
NIH / NIDCD · STTR phase I · $313K · posted 2026-07-01
- Home-based plasma self-collection device for remote diagnosis and monitoring of AD-associated biomarkersawardhigh relevance
NIH / NIA · SBIR phase I · $306K · posted 2025-09-25
- Development of an automated image enhancement system to improve point-of-care ultrasound imaging for out-of-hospital settingsawardhigh relevance
NIH / NIMHD · SBIR phase I · $337K · posted 2025-09-17
- Precise Wearable System for Accurate Continuous Gait Monitoring to Indicate Health Decline in Black Adults with Alzheimer's Disease and Related Dementiasawardhigh relevance
NIH / NIA · SBIR phase I · $500K · posted 2025-09-15
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Consumer
- Business model
- Hardware
- Path to 100x
- Collapses a cost 10x
- Market size
- $100B+ market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Real engineering
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- US first
- Regulation
- Some regulation
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-23 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.